Morepen Laboratories shares jumped 20% to ₹69.18 after the company reported a near fourfold increase in June quarter net profit to ₹56.4 crore. The sharp rise in earnings was driven by strong export growth and the successful launch of its new CDMO business. Investors are closely monitoring whether this margin expansion can be sustained in future quarters.
Morepen Laboratories saw its stock price climb 20% to reach ₹69.18 on the National Stock Exchange on Tuesday, marking the daily upper circuit limit. This positive market reaction follows the company’s financial results for the June quarter, where it recorded a consolidated net profit of ₹56.4 crore, compared to ₹10.8 crore in the same quarter last year.
Revenue Growth and Margin Improvement
The company reported a 34.1% year-on-year increase in revenue from operations, which rose to ₹570.1 crore from ₹425.2 crore. A major contributor to this performance was the sharp improvement in operating efficiency. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) reached ₹82.5 crore, a substantial increase from ₹24.2 crore a year ago. Consequently, the EBITDA margin improved significantly to 14.5% from 5.7% in the previous year's June quarter, reflecting a better product mix and lower relative costs.
Expansion Into CDMO Services
Beyond basic financial growth, the company’s strategic shift into the contract development and manufacturing organization (CDMO) space appears to be yielding results. Morepen Laboratories successfully initiated commercial supplies for its ₹825-crore CDMO mandate during this quarter, generating ₹58 crore in revenue from this segment alone. By moving toward this contract manufacturing model, the company aims to diversify away from its traditional focus on Active Pharmaceutical Ingredients (API).
Export Performance and Regulatory Standing
Exports played a major role in the quarter's success, with export revenue more than doubling, rising 111% year-on-year. The API business also saw a 31% growth, with API-specific exports climbing 42%. Additionally, the medical devices segment recorded a 19% increase. From a regulatory perspective, Morepen Laboratories recently completed its fourth consecutive USFDA inspection without receiving a Form 483, which is a document issued when inspectors find conditions that may constitute violations of the Food Drug and Cosmetic Act. This clean record is generally viewed as a positive indicator for companies looking to sustain or increase their export business to highly regulated markets like the United States.
Investors may look to track the consistency of these margins in future quarters and the pace at which the company executes the remaining balance of its large CDMO order book. As the company continues its plan to add manufacturing capacity, the impact on debt levels and the ability to maintain profitability amidst competitive pharmaceutical pricing will remain important monitorables.